



# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:


UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office

September 10, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 10/637,807  
FILING DATE: August 08, 2003  
RELATED PCT APPLICATION NUMBER: PCT/US04/25005

Certified by



Jon W Dudas

Acting Under Secretary of Commerce  
for Intellectual Property  
and Acting Director of the U.S.  
Patent and Trademark Office

Fee Transmittal

PTO/SB/05 (05-03)

Approved for use through 04/30/2003. OMB 0651-0032

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	257122/0033
First Inventor	Michael Burke
Title	ANTHELMINTIC FORMULATIONS
Express Mail Label No.	EL 895317725 US

03915 U.S. PTO  
10/637807  
08/08/03

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

## ADDRESS TO:

Commissioner for Patents  
Mail Stop Patent Application  
P.O. Box 1450  
Alexandria VA 22313-1450

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)
2. ☐ Applicant claims small entity status.  
See 37 CFR 1.27.
3. ☒ Specification (Total Pages 20)  
(preferred arrangement set forth below)
  - Descriptive title of the invention
  - Cross Reference to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to sequence listing, a table, or a computer program listing appendix
  - Background of the invention
  - Brief Summary of the invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
4. ☐ Drawing(s) (35 U.S.C. 113) (Total Sheets     )
5. Oath or Declaration (Total Sheets 4)
  - a. ☐ Newly executed (original or copy)
  - b. ☐ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 18 completed)
  - i. ☐ **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s)  
name in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☐ Application Data Sheet. See 37 CFR 1.76

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - a. ☐ Computer Reader Form (CRF)
  - b. Specification Sequence Listing on:
    - i. ☐ CD-ROM or CD-R (2 copies); or
    - ii. ☐ Paper
  - c. ☐ Statements verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney  
(when there is an assignee)
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure ☐ Copies of IDS Citations  
Statement (IDS/PTO-1499)
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
16. ☐ Nonpublication Request under 35 U.S.C. 122  
(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. ☒ Other: **Certificate of Mailing by Express Mail**

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: .....

Prior application information:

Examiner

Art Unit:

For CONTINUATION OF DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

## 19. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label

(Insert Customer No. or Attach bar code label here)

OR ☒ Correspondence address below

Name	Matthew W. Siegal				
Address	Stroock & Stroock & Lavan LLP				
	180 Maiden Lane				
City	New York	State	NY	Zip Code	10038
Country	United States	Telephone	212-806-5400	Fax	212-806-6006

Name (Print/Type)	Matthew W. Siegal	Registration No. (Attorney/Agent)	32,941
Signature	<i>[Signature]</i>	Date	August 8, 2003

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Docket No.  
257122/0033  
MWS:AEW

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Michael Burke, et al.

Group Art Unit: Not yet assigned

Application No.: Not yet assigned

Examiner: Not yet assigned

Filed: Herewith

For: ANTHELMINTIC FORMULATIONS

Date: August 8, 2003

**CERTIFICATE OF MAILING  
BY "EXPRESS MAIL" (37 C.F.R. § 1.10)**

**Mail Stop Patent Application**  
Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

I hereby certify that the following correspondence:


**Utility Patent Application Transmittal (1page), Application (19 pages), Unsigned Combined Declaration and Power of Attorney (4 pp.) and Acknowledgement Postcard**

is being deposited on August 8, 2003 with the United States Postal Service for "Express Mail Post Office to Addressee" delivery under 37 C.F.R. § 1.10 in an envelope bearing sufficient postage and addressed to:

**Mail Stop**  
**Commissioner for Patents**  
**PO Box 1450**  
**Alexandria, Virginia 22313-1450.**

**Amy E. Wilson**

(Typed Or Printed Name Of Person Mailing Correspondence)



(Signature Of Person Mailing Correspondence)

**EL 895317725 US**

("Express Mail" Mailing Label Number)

SSL-DOCS1 1367178

APPLICATION OF

**Michael Burke**

**Vinay Tripathi**

**Albert Ahn**

**and**

**Ian Cottrell**

FOR LETTERS PATENT OF THE UNITED STATES

For Improvements in

**ANTHELMINTIC FORMULATIONS**

Matthew W. Siegal  
Registration No. 32,941  
Attorney for Applicants  
Stroock & Stroock & Lavan, LLP  
180 Maiden Lane  
New York, New York 10038  
(212) 806-5400

Docket No. 257122/0033

## **ANTHELMINTIC FORMULATIONS**

### **BACKGROUND OF INVENTION**

[001] The invention relates generally to anthelmintic formulations which can have significant parasitocidal activity as anthelmintics, ectoparasiticides, insecticides and acaricides in animal health and more particularly to solid anthelmintic formulations containing ivermectin.

[002] Active ingredients of anthelmintics and their methods of formation in accordance with preferred embodiments of the invention are discussed in e.g. U.S. Patent Nos. 3,502,661, 4,001,411 and 4,199,569, the contents of which are incorporated herein by reference.

[003] It is often beneficial, under certain circumstances, to include multiple drugs in the same formulation in order to target a wider variety of parasites. One particularly desirable anthelmintic composition is ivermectin. Ivermectin is hygroscopic and therefore tends to be undesirably unstable. It has also been seen that Ivermectin is unstable in both acidic and basic solutions and is susceptible to photodegradation and oxidative degradation. Accordingly, it is very difficult to prepare a solid composition, such as a tablet, containing ivermectin without having to resort to using a large amount of filler material to make up the bulk of the tablet in order to maintain the integrity of the compound and even then, degradation problems can exist. This problem is compounded when additional drugs are intended to be included in the same formulation, as ivermectin can degrade other drugs.

[004] Accordingly, it is desirable to provide a multidrug anthelmintic formulation in solid form that can be formed into a solid or tablet of optimal size, palatable to animals and which can be easily administered to the affected animal.

## **SUMMARY OF THE INVENTION**

[005] Generally speaking, in accordance with the invention, a pharmaceutical formulation is provided for use in the treatment of helminthiasis of mammals, and particularly tapeworm, hookworm, roundworm and heartworm of domestic animals and farm animals. Accordingly, the present invention provides a method of treating helminthiasis in mammals, which method comprises administering to the mammal in need thereof, an anthelmintically effective amount of a pharmaceutical formulation of the invention. The present invention also provides a composition and a method for preparing a pharmaceutical formulation containing ivermectin and a method and composition that can contain ivermectin plus other active compositions such as hexahydropyrazinoisoquinolines and anthelmintic pyrimidines such as tetrahydropyrimidines. Examples of these include praziquantel and pyrantel, respectively. Formulations in accordance with the invention can remain stable for over one month, and typically, much longer.

[006] One preferred method involves isolating the ivermectin through granulation in particular, spray granulation. The other drugs can also be granulated or spray granulated. The granules can be left in a powder form, tableted or encapsulated. One method of preparation of the formulation comprises the following steps:

- (a) preparing a first and second or a first, second and third (or more) combination including the first and second or the first, second and third active ingredient, respectively;
- (b) combining the combinations from (a) with dispersing agents to form two or three separate aqueous solutions;
- (c) granulating one or all of the solutions, especially by spray granulation, from (b) by combining with a dry combination;

- (d) drying the resulting granules, if needed;
- (e) blending the granules from (d), which contain the first, second (and third) active ingredients and an excipient combination; and
- (f) forming the blended granules into tablets or capsules or leaving in powder form.

### **DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS**

[007] The present invention relates to anthelmintic active compound combinations including avermectins, hexahydropyrazinoisoquinolines and anthelmintic pyrimidines such as tetrahydropyrimidines. Acceptable tetrahydropyrimidines include, for example, pyrantel, morantel and oxantel. Acceptable hexahydropyrazinoisoquinolines include, for example, praziquantel. Other acceptable actives include benzazepines and salicylamides. Acceptable avermectins include, for example, ivermectin, doramectin, selamectin and abamectin.

[008] A formulation of active ingredients comprising ivermectin, praziquantel and pyrantel is particularly preferred. The active ingredients target different pathogenic organisms that can adversely affect the health of a mammal. This particular combination is particularly effective in fighting a wide variety of organisms. However, administering three physically separate pharmaceutical compositions to an animal is undesirable and it has been determined that it would be beneficial to combine the ingredients into one formulation, in particular one tablet (or capsule) containing a pharmaceutically effective amount of the active ingredients, thereby decreasing the number of administrations of formulations to the animal.

[009] The disease or group of diseases described generally as helminthiasis is due to infestation of an animal host with parasitic worms known as helminths. Helminthiasis is a prevalent and serious economic problem in domesticated animals such as swine, sheep, horses, cattle, goats,

dogs, cats and poultry. Among the helminths, the group of worms described as nematodes causes widespread and often times serious infection in various species of animals. Still other parasites may be located in other tissues and organs of the body such as the heart and blood vessels, subcutaneous and lymphatic tissue and the like. The parasitic infections known as helminthiasis lead to anemia, malnutrition, weakness, weight loss, severe damage to the walls of the intestinal tract and other tissues and organs and, if left untreated, may result in death of the infected host.

[0010] Although the antiparasitic agents of this invention find their primary use in the treatment and/or prevention of helminthiasis, they are also useful in the prevention and treatment of diseases caused by other parasites, for example, arthropod parasites such as ticks, lice, fleas, mites and other biting insects in domesticated animals and poultry. Repeat treatments are given as required to combat re-infestations and are dependent upon the species of parasite. The techniques for administering these materials to animals are known to those skilled in the veterinary field.

[0011] The preparations are suitable for combating pathogenic endoparasites which occur in animal husbandry and animal breeding in productive, breeding, zoo, laboratory, experimental animals and pets, and have a favorable toxicity to warm-blooded animals. In this connection, they are active against all or individual stages of development of the pests and against resistant and normally sensitive species. By combating pathogenic endoparasites, it is intended that disease, cases of death and reduction in production (for example in the production of meat, milk, wool, hides, eggs, etc.) are reduced so that more economic and simpler animal husbandry is possible by means of the use of the pharmaceutical formulation.



[0012] The productive and breeding animals include mammals, such as, for example, cattle, horses, sheep, pigs, goats, camels, water buffalo, donkeys, rabbits, fallow deer and reindeer, pelt animals, such as, for example, mink, chinchilla and raccoons, birds, such as, for example, chickens, geese, turkeys and ducks, fresh and salt-water fish, such as, for example, trout, carp and eels, and reptiles.

[0013] The laboratory and experimental animals include mice, rats, guinea pigs, golden hamsters, dogs and cats.

[0014] The pets include dogs and cats.

[0015] The formulation according to the invention is particularly preferably administered to dogs and cats, but is suitable for other mammals.

[0016] Administration can take place both prophylactically and therapeutically.

[0017] The formulations can be administered directly or in the form of suitable preparations, enterally, parenterally or dermally.

[0018] Enteral administration of the formulations takes place, for example, orally in the form of powder, tablets, capsules, pastes, potions, granules, orally administered solutions, suspensions and emulsions, boli, medicated feed or drinking water.

[0019] Suitable preparations are:

oral solutions and concentrates for oral administration after dilution;

emulsions and suspension for oral administration; and semisolid preparations;

formulations in which the active compound is processed in an ointment base or in an oil-in-water or water-in-oil emulsion base;

solid preparations, such as powders, premixes or concentrates, granules, pellets, tablets, boli and capsules, with tablets the preferred form;

oral solutions are prepared by dissolving the active compound in a suitable solvent and, if appropriate, adding additives such as solubilizers, acids, bases, buffer salts, antioxidants and preservatives. The solutions are filtered and packed under sterile conditions.

[0020] Solvents may include: physiologically acceptable solvents, such as water, alcohols, such as ethanol, butanol, benzyl alcohol, glycerol, propylene glycol and polyethylene glycol, N-methylpyrrolidone, and mixtures of the same.

[0021] The active compounds can, if appropriate, also be dissolved in physiologically acceptable vegetable or synthetic oils.

[0022] Solubilizers may include: solvents which promote dissolution of the active compound in the main solvent or substances which prevent precipitation of the active compound. Examples are polyvinyl pyrrolidone, polyoxyethylated castor oil and polyoxyethylated sorbitan esters.

[0023] One particularly preferred formulation of the invention, comprising three active ingredients, is preferably administered in the form of capsules, more preferably tablets. A preferred formulation of the present invention contains 0.005 - 25% ivermectin, preferably 0.01 - 15%, and most preferably 0.012 - 5%, with 0.016% as a preferred example. A preferred formulation of the present invention can contain 2.0 - 58% of a secondary anthelmintic drug, such as an isoquinoline, preferably praziquantel, preferably 6 - 41%, and most preferably 11.2 - 23%, with 13.6% as a preferred example. A preferred formulation of the present invention can contain 1.5 - 76% of an anthelmintic pyrimidine, preferably pyrantel, preferably 6 - 52%, and

most preferably 11.2 – 23%, with 13.6% as a preferred example. All percentages herein, unless otherwise evident, are on a weight basis.

[0024] A preferred dosage of avermectin, e.g., ivermectin, is about 5 – 7 µg/Kg body weight of the animal administered monthly, preferably 5.5 – 6.5 µg/Kg body weight, with 6 µg/Kg body weight as a preferred example. A preferred dosage of anthelmintic pyrimidines, e.g., pyrantel, is about 4.25 – 5.75 mg/Kg body weight administered monthly, preferably 4.75 – 5.25 mg/Kg, with 5 mg as a preferred example. A preferred dosage of hexahydropyrazinoisoquinoline, e.g., praziquantel, is about 4.25 – 5.75 mg/Kg body weight administered monthly, preferably 4.75 – 5.25 mg/Kg, with 5 mg as a preferred example.

[0025] To prepare solid preparations, the active compound should be mixed with suitable excipients, if appropriate, with addition of auxiliaries, and converted to the form desired.

[0026] One preferred method of preparation of the formulation comprises the following steps:

- (a) preparing a first, or a first and second, or a first, second and third combination including the first, or the first and second, or the first, second and third active ingredient, respectively, or of course, formulations involving more than three active ingredients;
- (b) combining the combinations from (a) with dispersing agents comprising carrier material to form one, two or three separate aqueous solutions;
- (c) granulating one or all of the solutions, preferably by spray granulation, from (b)
- (d) drying the resulting granules, if needed;

(e) blending the granules from (d), which contain the first, second and third active ingredients and carrier material; and

(f) if desired, forming the blended granules into tablets or filling a capsule.

[0027] Spray granulation involves the drying of liquid (*i.e.*, solution, suspension melt and so forth) while simultaneously building particle size. By mixing an active ingredient with a carrier in the liquid phase, the active can become “encapsulated” or substantially covered in a matrix of carrier after the spray granulation process. Granulation is generally performed by spraying liquid into the fluidized powder. The granules are subsequently dried with heated air.

[0028] Suitable excipients may include physiologically acceptable inert solids such as, for example, sodium chloride, calcium carbonate, hydrogen carbonates, aluminum oxides, silicas, clays, precipitated or colloidal silicon dioxide and phosphates. Other suitable excipients may include, for example, sugar, cellulose, Croscarmellose Sodium, Aerosil, nutrients and feedstuffs, such as milk powder and pork liver powder, animal meals, ground and crushed cereal meals, Avicel PH102 and starches.

[0029] Auxiliaries can include preservatives, antioxidants and colorants. Additional suitable auxiliaries can include lubricants, such as, for example, magnesium stearate, stearic acid, talcum and bentonites, disintegration-promoting substances, such as starch or transversely crosslinked polyvinyl pyrrolidone, binders, such as, for example, starch, gelatin or linear polyvinyl pyrrolidone, and dry binders, such as microcrystalline cellulose.

[0030] The formulation can also be in the form of a chewable, such as a beef-chewable containing ground or minced beef or other meat, in addition to other excipients listed above.

[0031] The materials in the final formulation, such as the excipients, auxiliaries, synergists and other materials, which aid in delivery, shelf-life, desired physical structure and so forth will be

referred to herein generally as carrier material. As stated herein, carrier material could be pharmaceutically active under certain circumstances.

[0032] The following example is given for purposes of illustration only and is not intended to be construed in a limiting manner.

**EXAMPLE 1: Preparation of Tablets Containing Ivermectin, Praziquantel and Pyrantel**

[0033] Three separate mixtures were prepared as follows:

[0034] Mixture A:

[0035] Table 1

<b>Ingredient</b>	<b>Amount (g)</b>	<b>% w/w</b>
Ivermectin	8.3	0.02
Microcrystalline Cellulose USP (Avicel PH102)	2640.0	5.28
Povidone K30	2143.0	4.29
Croscarmellose Sodium	855.0	1.71
Polyethylene Glycol 8005	500.0	1.0
Citric Acid Anhydrous	10.4	0.02
Sodium Citrate Dihydrate	3.5	0.007
Purified Water	1961.5	

[0036] The ingredients were dispensed in the amounts specified in Table 1.

[0037] The following materials (in the order listed below) were passed through a Russel Sieve fitted with 20# sieve and collected in a stainless steel drum:

(a) Avicel PH102

(b) Croscarmellose Sodium

(c) Povidone

[0038] The delumped material resulting from the step above was added to the drum tumbler and blended for 20 minutes. Purified water was added to a stock pot with citric acid and sodium citrate dihydrate. The contents were mixed for 5 minutes with a stirring rod.

[0039] Polyethylene glycol flakes were added to a separate stock pot and heated with a water bath to a temperature of  $45 \pm 5^\circ \text{C}$  to melt the flakes. The solution was maintained at this temperature. Ivermectin was added to the melted polyethylene glycol with gentle stirring until the compound was dissolved. The solution was maintained at  $45 \pm 5^\circ \text{C}$ .

[0040] 161.5g of the citrate buffer detailed above was added to the melted polyethylene glycol/ivermectin solution and stirred with gentle agitation for at least 5 minutes until the solution was clear. The stirring was then ceased to allow any air bubbles to escape and the solution was maintained at  $45 \pm 5^\circ \text{C}$ .

[0041] The remaining citrate buffer solution was placed on a hot plate and heated to a temperature of  $55 \pm 5^\circ \text{C}$ .

[0042] The blended Avicel, Croscarmellose Sodium and Povidone was transferred to a spray granulator. The solutions were spray granulated as follows:

(a) The spray granulator was programmed with the following parameters:

- (1) inlet air temperature:  $50 \pm 10^\circ \text{C}$
- (2) outlet air temperature:  $45 \pm 10^\circ \text{C}$
- (3) bed temperature:  $43 \pm 10^\circ \text{C}$
- (4) atomization pressure: 3 - 5 bar
- (5) spray rate:  $100\text{g} \pm 20\text{g}$  per minute
- (6) pan speed: 2 - 10 rpm

(a) The ivermectin/polyethylene glycol/citrate buffer solutions was sprayed at a rate of  $100 \pm 20$  g/minute until all of the solution was sprayed.

(b) The reserve citrate buffer at  $55 \pm 5^\circ \text{C}$  was added to the container which held the previous solution for rinsing purposes. The rinse citrate buffer was sprayed at a rate of  $100 \pm 20 \text{ g/minute}$ .

(c) Granulation was continued by spraying 300g of purified water at room temperature. Additional purified water was sprayed until the desired consistency was achieved.

[0043] The granules were then emptied into the drying bowl and dried using a fluid bed drier. After drying, the bowl was removed and the granules were mixed with a scoop. The dried granules obtained were transferred in double polythene lined suitable container.

[0044] Mixture B:

[0045] Table 2:

Ingredient	Amount (g)	% w/w
Pyrantel Pamoate	19,536.0	39.07
Microcrystalline Cellulose USP (Avicel PH102)	2,285.0	4.57
Croscarmellose Sodium	810.0	1.62
Povidone K30	630.0	1.26

[0046] The ingredients were dispensed in the amounts specified in Table 2.

[0047] The following materials (in the order listed below) were passed through a Russel Sieve fitted with 20# sieve and collected in a suitable container:

(a) Pyrantel Pamoate

(b) Povidone

(c) Croscarmellose Sodium

(d) Avicel PH102

[0048] The sieved material was added to a Diosna mixer and blended for 10 minutes using the impeller on low speed with the chopper off. The mixture was granulated with 9,000g of purified water with the impeller and the chopper set on low speed. Additional purified water was added to achieve the good granular mass.

[0049] The granulated mixture was dried using a fluid bed drier and transferred to a double polythene lined suitable container.

[0050] Mixture C:

[0051] Table 3:

Ingredient	Amount (g)	% w/w
Praziquantel USP	6,786.0	13.57
Povidone K30	715.0	1.43
Croscarmellose Sodium	835.0	1.67
Polymethacrylate USP (Eudragit E-100)	2,530.0	5.06
Citric Acid Anhydrous	789.4	1.58
Microcrystalline Cellulose USP (Avicel PH102)	1,785.0	4.57
Purified Water		

[0052] The ingredients were dispensed in the amounts specified in Table 3.

[0053] The following materials (in the order listed below) were passed through a Russel Sieve fitted with 20# sieve and collected in a stainless steel drum:

- (a) Praziquantel USP
- (b) Povidone
- (c) Croscarmellose Sodium
- (d) Avicel PH102

[0054] The delumped material was mixed in a drum tumbler for 20 minutes. The mixture was added to a Diosna mixer and 10 L of purified water was gradually added with the impeller on low speed with the chopper activated for 5 minutes. The choppers were set on fast speed and run



for 3 minutes. The granules were dried in a fluid bed drier and transferred to a double polythene lined suitable container.

[0055] 13,658 g of purified water was added to a stock pot and mixed with medium agitation.

Citric acid and Eudragit E-100 was added to the stock pot. The mixture was stirred with medium agitation until the components had completely dissolved. The resulting Eudragit solution was allowed to settle until the air bubbles had escaped.

[0056] The praziquantel granulated mixture was added to the spray granulator and coated with the Eudragit E-100 solution. The resulting material was transferred to a double polythene lined suitable container.

[0057] Excipient Mixture:

[0058] Table 4:

Ingredient	Amount (g)	% w/w
SD Pork Liver Powder	4,048.0	8.10
Avicel PH102	1,663.0	3.33
Croscarmellose Sodium	778.0	1.58
Aerosil	150.0	0.30
Magnesium Stearate	500.0	1.00

[0059] The ingredients were dispensed in the amounts specified in Table 4.

[0060] The first four excipients were sifted through a 500# sieve and collected in a suitable container. Then the Magnesium Stearate was sifted through a 500# mesh sieve. The three mixtures containing the active ingredients of the formulation (*i.e.*, Mixtures A, B and C) and the excipient mixture were blended in a drum tumbler for 25 minutes. The sifted Magnesium Stearate was added and blended for an additional 5 minutes.

[0061] The formulation was then compressed into a plain round concave tablets of 420mg or 840mg and caplets of 1680mg.

[0062] It will thus be seen that the objects set forth above, among those made apparent from the preceding description, are efficiently attained and, since certain changes may be made in carrying out the above method and in the composition set forth without departing from the spirit and scope of the invention, it is intended that all matter contained in the above description shall be interpreted as illustrative and not in a limiting sense.

[0063] It is also to be understood that the following claims are intended to cover all of the generic and specific features of the invention herein described and all statements of the scope of the invention which, as a matter of language, might be said to fall therebetween. Particularly it is to be understood that in said claims, ingredients or compounds recited in the singular are intended to include compatible mixtures of such ingredients wherever the sense permits.

## **CLAIMS**

What is claimed is:

1. A pharmaceutically acceptable anthelmintic formulation comprising a first active ingredient comprising an avermectin; a second active ingredient comprising a tetrahydropyrimidine; and a third active ingredient, comprising a hexahydropyrazinoisoquinoline.
2. The formulation of claim 1, wherein the first active ingredient comprises ivermectin.
3. The formulation of claim 1, comprising at least about 0.005% ivermectin.
4. The formulation of claim 1, comprising about 0.012 – 5% ivermectin.
5. The formulation of claim 1, comprising an anthelmintic pyrimidine.
6. The formulation of claim 1, wherein the second active ingredient comprises pyrantel.
7. The formulation of claim 1, comprising at least about 1.5% pyrantel.
8. The formulation of claim 1, comprising about 11.2 – 23% pyrantel.
9. The formulation of claim 1, wherein the third active ingredient comprises praziquantel.
10. The formulation of claim 1, comprising at least about 2.0% praziquantel.
11. The formulation of claim 1, comprising about 11.2 – 23% praziquantel.
12. The formulation of claim 2, in a form that will remain stable and pharmaceutically active, in a solid form, for over one month.
13. The formulation of claim 1, comprising a benzazepine or a salicylamide.
14. The formulation of claim 12, wherein there is an effective amount of pharmaceutically acceptable carrier material to prevent the ivermectin from degrading sufficiently to eliminate its pharmaceutical effectiveness.

15. An anthelmintic formulation, which is in the form of a tablet, comprising an ivermectin; a tetrahydropyrimidine; a hexahydropyrazinoisoquinoline; and a suitable carrier, in a condition that will remain active and in its tablet form for over one month.

16. The formulation of claim 15, comprising ivermectin that has been granulated with carrier material surrounding the ivermectin.

17. A method for forming an anthelmintic formulation comprising the steps of: preparing a combination of ivermectin and a second material, then spray granulating the combination to form granules, with the second material covering the ivermectin.

18. The method of claim 17, comprising combining the granules with an additional active ingredient composition.

19. The method of claim 18, wherein the additional ingredient composition comprises pyrantel or praziquantel.

20. The method of claim 19, wherein the second active ingredient comprises benzazepine or a salicyamide.

21. The method of claim 17, comprising adding an anthelmintic pyrimidine to the formulation.

22. The method of claim 19, wherein the formulation is pressed into a tablet or enclosed in a capsule and the ivermectin has been effectively isolated, so that the formulation will stay stable for over one month.

23. The anthelmintic formulation, which is formed by the method of claim 17.

24. The method of controlling helminth infestation in animals, comprising administering a pharmaceutically effective amount of the formulation of claim 2 to an animal in need thereof.

25. The method claim 24, wherein the animal is a dog or cat.

26. The method claim 24, wherein the administration comprises administering 5 –7  $\mu\text{g/Kg}$  body weight of the animal dog or cat.

27. A method of forming an anthelmintic formulation comprising combining ivermectin with carrier material and spray granulating the ivermectin to effectively isolate the ivermectin and maintain the ivermectin stable for over one month.

## **ABSTRACT**

The present invention provides a method for preparing a pharmaceutical formulation containing ivermectin and a method and composition that can contain ivermectin plus hexahydropyrazinoisoquinolines and tetrahydropyrimidines. Examples of these include praziquantel and pyrantel. A pharmaceutical formulation is provided for use in the treatment of helminthiasis of mammals, and particularly tapeworm, hookworm, roundworm and heartworm of domestic animals and farm animals. The present invention also provides a method of treating helminthiasis in mammals, which method comprises administering to the mammal in need thereof an anthelmintically effective amount of a pharmaceutical formulation of the invention.

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/025005

International filing date: 03 August 2004 (03.08.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 10/637,807  
Filing date: 08 August 2003 (08.08.2003)

Date of receipt at the International Bureau: 17 September 2004 (17.09.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse